In type 2 diabetes, the body's ability to release insulin is impaired, which leads to high blood glucose levels. Research led ...

Most mutations which cause disease by swapping one amino acid out for another do so by making the protein less stable, according to a massive study of human protein variants published in the journal ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

If you are prediabetic — a condition when your blood sugar levels are higher than normal but not high enough to be diagnosed ...

Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Diamyd Medical announces the publication of the article titled "Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial" in the peer-reviewed journal Inte ...

Stanford Medicine researchers are using artificial intelligence to help identify the underlying biology behind Type 2 diabetes.